布地奈德福莫特罗粉吸入剂联合甲泼尼龙治疗重症支气管哮喘的临床疗效及其对炎性反应的影响  

Clinical efficacy of budesonide and formoterol fumarate powder for inhalation combined with methylprednisolone in the treatment of severe bronchial asthma and its effect on inflammatory response

作　　者：张明凤 马海彬[1] 张德良 ZHANG Mingfeng;MA Haibin;ZHANG Deliang(Department of Respiratory Medicine,the Second Hospital of Longyan,Longyan 364000,China)

机构地区：[1]福建省龙岩市第二医院呼吸内科,364000

出　　处：《临床合理用药杂志》2022年第36期13-16,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察布地奈德福莫特罗粉吸入剂联合甲泼尼龙治疗重症支气管哮喘的临床疗效及其对炎性反应的影响。方法选取2020年1月—2022年1月龙岩市第二医院收治的重症支气管哮喘患者120例作为研究对象,按照随机数字表法分为单一组与联合组,每组60例。单一组予以甲泼尼龙片,联合组在单一组基础上加用布地奈德福莫特罗粉吸入剂,2组均治疗12周。比较2组临床疗效,治疗前后炎性反应指标[肿瘤坏死因子α(TNF-α)和白介素6(IL-6)]、哮喘控制测试(ACT)评分、肺功能指标[第1秒用力呼气容积(FEV_(1))、FEV_(1)与用力肺活量比值(FEV_(1)/FVC)],健康状况调查问卷(SF-36)评分,药物不良反应。结果联合组治疗总有效率为93.33%,高于单一组的73.33%(χ^(2)=8.640,P=0.003)。治疗后,2组FEV_(1)、FEV_(1)/FVC、ACT评分高于治疗前,且联合组高于单一组(P<0.05)。治疗后,2组TNF-α、IL-6水平低于治疗前,且联合组低于单一组(P<0.01)。联合组SF-36评分高于单一组(P<0.01)。联合组不良反应总发生率为10.00%,低于单一组的25.00%(χ^(2)=4.675,P=0.031)。结论布地奈德福莫特罗粉吸入剂联合甲泼尼龙治疗重症支气管哮喘的临床疗效确切,能够有效改善患者的临床症状及肺功能,减轻炎性反应,且安全性较高。Objective To observe clinical efficacy of budesonide and formoterol fumarate powder for inhalation combined with methylprednisolone in the treatment of severe bronchial asthma and its effect on inflammatory response.Methods A total of 120 cases of patients with severe bronchial asthma were selected from January 2020 to January 2022 in the Second Hospital of Longyan,which were divided into single group and combined group according to the random number table method,with 60 cases in each group.The single group was given methylprednisolone tablets,and the combined group was given budesonide and formoterol fumarate powder for inhalation on the basis of the single group.The single group and the combined group were treated for 12 weeks.Clinical efficacy,inflammatory response index(TNF-α,IL-6),ACT score,pulmonary function indexex(FEV_(1),FEV_(1)/FVC)before and after treatment,SF-36 score were compared between the two groups,and the incidence of adverse reactions were observed.Results The total effective rate of combined group was 93.33%,which was higher than 73.33%of single group(χ^(2)=8.640,P=0.003).After treatment,FEV_(1),FEV_(1)/FVC and ACT score of the two groups were higher than those before treatment,and the combined group were higher than those of the single group(P<0.05).After treatment,the levels of TNF-αand IL-6 in the two groups were lower than those before treatment,and those in the combined group were lower than those in the single group(P<0.01).The SF-36 score of the combined group was higher than single group(P<0.01).The total incidence of adverse reactions in the combined group was 10.00%,which was lower than that in the single group(25.00%)(χ^(2)=4.675,P=0.031).Conclusion Budesonide and formoterol fumarate powder for inhalation combined with methylprednisolone have an exact clinical effect for severe bronchial asthma,which can effectively improve the clinical symptoms and pulmonary function of patients,reduce inflammatory reaction,and has high safety.

关 键 词：重症支气管哮喘 布地奈德福莫特罗粉吸入剂 甲泼尼龙 治疗结果 

分 类 号：R562.25[医药卫生—呼吸系统]